Skip to content

Appropriate Medication Use for Individuals With Intellectual Disabilities - A Matter of Life

Appropriate Medication Use for Individuals With Intellectual Disabilities - A Matter of Life

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06160102
Enrollment
110
Registered
2023-12-07
Start date
2023-08-15
Completion date
2027-07-31
Last updated
2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disabilities, Intellectual, Disability, Developmental

Keywords

Intellectual Disabilities, Developmental Disabilities, Intersectoral Collaboration, Medication Therapy Management, Medication Reconciliation, Medication Review

Brief summary

The innovation idea is to develop valuable new knowledge about safe drug use in people with intellectual and/or developmental disabilities (IDDs). The main goal is to design a framework (routines and processes) that ensures safe drug use and provides qualitatively better services for people with IDDs. Secondary goals are that employees will experience better security when working with medicines, and interact better with people with IDD and relatives by implementing digital support functions. The innovation idea is specifically to develop/improve the following: 1) Medication management: Coordinating routines, procedures and work processes regarding all aspects of drug use, medication handling, and communication between care units for people with IDDs. 2) Medication therapy: Chart review of prescribed medication and gather knowledge about challenges related to drug use in this group. Based on this, we will develop new methods for drug reconciliation and medication reviews to optimize drug use. 3) New framework for safe drug use in the community-based services for people with IDDs.

Detailed description

Changing, developing, and testing new routines, procedures, and communication methods for safe drug use is challenging. The complexity of systems that are involved in medication management makes it particularly challenging to create well-designed digital solutions that ensure good working procedures. The complex issues faced by people with IDDs, as well as developments within personalized medicine, means that it is crucial to build new knowledge, work in teams, and arrange for medication reconciliation and medication reviews to be carried out regularly. Furthermore, drug information must be provided, and adapted to the specific individual with an intellectual disability. In addition, the focus on personalized medicine means that the municipality must develop new guidelines for the use of pharmacogenetic tests so that the doctor can tailor drug selection and dosage to the individual patient.

Interventions

OTHERDevelop and implement the Framework for safe drug use in people with intellectual and/or developmental disabilities

Collection and analysis of drug lists and information about the users. Open / participatory observations of staff and residents during drug handling. Interviews/focus groups with residents, family, staff in the service, GPs and pharmacy staff. Interdisciplinary drug reviews based on the IMM method drug reviews, further developed by the researchers in the project. Design thinking. We use a design process with five stages: empathy, define, generate ideas, prototype and test. This involves user participation and experience to design the most optimal solution for the framework. Evaluate the framework, observations, interviews, questionnaires. Health economic evaluation.

Sponsors

University of Oslo
CollaboratorOTHER
University of Tromso
CollaboratorOTHER
Vestvagoy Municipality
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

Participatory action research

Eligibility

Sex/Gender
ALL
Age
1 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Users of the municipality's Service for people with disabilities

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
To understand what is safe drug therapy and drug handling in people with intellectual and/or developmental disabilities12 monthsMap which drugs each patient uses and carry out medication reconciliation (nurse and pharmacist) and medication review (nurse, pharmacist and general general practitioner). Interviews of employees, GPs and pharmacy staff.
Formulation of multidisciplinary frameworks for optimizing drug handling and drug therapy.18 monthsDesign thinking and co-creation of multidisciplinary frameworks
Explore usefulness of multidisciplinary frameworks18 monthsTranscripts of qualitative feedback. Follow-up survey of employees, GPs, pharmacy staff, and people with intellectual and/or developmental disabilities. Health economic evaluation.

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026